MDACC Study No:2013-0416 ( NCT No: NCT01721876)
Title:A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients >/= 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy
Principal Investigator:Jorge Cortes
Treatment Agent:Volasertib
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if volasertib combined
with cytarabine can help to control AML. This will be compared with a placebo
combined with cytarabine. The safety of these treatments will also be studied.

A placebo is not a drug. It looks like the study drug but is not designed to
treat any disease or illness. It is designed to be compared with a study drug
to learn if the study drug has any real effect.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase III
Treatment Agents:Volasertib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Boehringer Ingelheim
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults